<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02822599</url>
  </required_header>
  <id_info>
    <org_study_id>NCH0000201496</org_study_id>
    <nct_id>NCT02822599</nct_id>
  </id_info>
  <brief_title>Human Fibrinogen Concentrate in Pediatric Cardiac Surgery</brief_title>
  <acronym>RiaSTAP</acronym>
  <official_title>The Role of Human Fibrinogen Concentrate (RiaSTAP) in Decreasing Blood Loss and the Need for Component Blood Therapy in Infants Undergoing Cardiopulmonary Bypass.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nicklaus Children's Hospital f/k/a Miami Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nicklaus Children's Hospital f/k/a Miami Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the study is to determine whether the use of Human Fibrinogen Concentrate
      (RiaSTAP) will decrease blood loss and the need for component blood therapy in neonates and
      infants undergoing cardiopulmonary bypass.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of the study is to determine whether the use of Human Fibrinogen Concentrate
      (RiaSTAP) will decrease blood loss and the need for component blood therapy in neonates and
      infants undergoing cardiopulmonary bypass. RiaSTAP will be administered after termination of
      Cardiopulmonary Bypass (CPB) at a dose of 70 mg/kg, in a prospective, randomized, controlled
      study. We hypothesize that the administration of RiaSTAP in this manner will reduce
      peri-operative bleeding and transfusion requirements.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patients suffering from postoperative bleeding after surgery</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>Primary efficacy endpoint to measure bleeding cc/kg, identity and total volume of transfused blood products</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-Op End Points - Adverse Events</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>Patients requiring ventilator support, LOS in the CICU, re-exploration for bleeding, LOS in the hospital, monitoring of adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hypofibrinogenemia</condition>
  <condition>Afibrinogenemia</condition>
  <condition>Bleeding Disorders</condition>
  <arm_group>
    <arm_group_label>RiaSTAP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 1 will receive an infusion of RiaSTAP after termination of CPB at a dose of 70 mg/kg after randomization to this group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group 2 will receive a placebo consisting of Normal Saline 0.9% (NS) after randomization to this group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RiaStAP</intervention_name>
    <description>To decrease post-operative bleeding volume.</description>
    <arm_group_label>RiaSTAP</arm_group_label>
    <other_name>Fibrinogen Concentrate Human</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Placebo consisting of normal saline 0.9%</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>Normal Saline 0.9%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Neonatal and infant cardiac patients presenting for open-heart surgery at Nicklaus
             Children's Hospital will be eligible for enrollment in the study.

        Exclusion Criteria:

          -  Patients who fall outside of the age range for the study will be excluded. Patients
             known to have had an anaphylactic or severe reaction to the drug or its components
             will not be enrolled. At the time of the rewarming ROTEM, any patient with a FIBTEM
             MCF &gt; 15mm, will be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Year</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Tirotta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director Cardiac Anesthesia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jenny Esteves, RRC</last_name>
    <phone>786-624-2854</phone>
    <email>jenny.esteves@nicklaushealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anabel Rodriguez, CCRC</last_name>
    <phone>786-624-2590</phone>
    <email>anabel.rodriguez@nicklaushealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nickalus Children's Hospital f/k/a Miami Children's Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny Esteves, RRC</last_name>
      <phone>786-624-2854</phone>
      <email>jenny.esteves@nicklaushealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Anabel Rodriguez, CCRC</last_name>
      <phone>786-624-2590</phone>
      <email>anabel.rodriguez@nicklaushealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Christopher Tirotta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nicklaus Children's Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Tirotta, MD</last_name>
      <phone>305-666-6511</phone>
      <email>christopher.tirotta@nicklaushealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Anabel Rodriguez, CCRC</last_name>
      <phone>786-624-2590</phone>
      <email>anabel.rodriguez@nicklaushealth.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.nicklauschildrens.org/home</url>
    <description>Nicklaus Children's Hospital</description>
  </link>
  <reference>
    <citation>Dacey LJ, Munoz JJ, Baribeau YR, Johnson ER, Lahey SJ, Leavitt BJ, Quinn RD, Nugent WC, Birkmeyer JD, O'Connor GT. Reexploration for hemorrhage following coronary artery bypass grafting: incidence and risk factors. Northern New England Cardiovascular Disease Study Group. Arch Surg. 1998 Apr;133(4):442-7.</citation>
    <PMID>9565127</PMID>
  </reference>
  <reference>
    <citation>Moulton MJ, Creswell LL, Mackey ME, Cox JL, Rosenbloom M. Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations. J Thorac Cardiovasc Surg. 1996 May;111(5):1037-46.</citation>
    <PMID>8622301</PMID>
  </reference>
  <reference>
    <citation>Paparella D, Brister SJ, Buchanan MR. Coagulation disorders of cardiopulmonary bypass: a review. Intensive Care Med. 2004 Oct;30(10):1873-81. Epub 2004 Jul 24. Review.</citation>
    <PMID>15278267</PMID>
  </reference>
  <reference>
    <citation>Miller BE, Tosone SR, Guzzetta NA, Miller JL, Brosius KK. Fibrinogen in children undergoing cardiac surgery: is it effective? Anesth Analg. 2004 Nov;99(5):1341-6; table of contents.</citation>
    <PMID>15502028</PMID>
  </reference>
  <reference>
    <citation>Kern FH, Morana NJ, Sears JJ, Hickey PR. Coagulation defects in neonates during cardiopulmonary bypass. Ann Thorac Surg. 1992 Sep;54(3):541-6.</citation>
    <PMID>1510523</PMID>
  </reference>
  <reference>
    <citation>Chan AK, Leaker M, Burrows FA, Williams WG, Gruenwald CE, Whyte L, Adams M, Brooker LA, Adams H, Mitchell L, Andrew M. Coagulation and fibrinolytic profile of paediatric patients undergoing cardiopulmonary bypass. Thromb Haemost. 1997 Feb;77(2):270-7. Erratum in: Thromb Haemost 1997 May;77(5):1047.</citation>
    <PMID>9157580</PMID>
  </reference>
  <reference>
    <citation>Karlsson M, Ternstr√∂m L, Hyllner M, Baghaei F, Nilsson S, Jeppsson A. Plasma fibrinogen level, bleeding, and transfusion after on-pump coronary artery bypass grafting surgery: a prospective observational study. Transfusion. 2008 Oct;48(10):2152-8. doi: 10.1111/j.1537-2995.2008.01827.x. Epub 2008 Jul 24.</citation>
    <PMID>18657083</PMID>
  </reference>
  <reference>
    <citation>Karlsson M, Ternstr√∂m L, Hyllner M, Baghaei F, Flinck A, Skrtic S, Jeppsson A. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery. A prospective randomised pilot study. Thromb Haemost. 2009 Jul;102(1):137-44. doi: 10.1160/TH08-09-0587.</citation>
    <PMID>19572078</PMID>
  </reference>
  <reference>
    <citation>Rahe-Meyer N, Pichlmaier M, Haverich A, Solomon C, Winterhalter M, Piepenbrock S, Tanaka KA. Bleeding management with fibrinogen concentrate targeting a high-normal plasma fibrinogen level: a pilot study. Br J Anaesth. 2009 Jun;102(6):785-92. doi: 10.1093/bja/aep089. Epub 2009 May 2.</citation>
    <PMID>19411671</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2016</study_first_submitted>
  <study_first_submitted_qc>July 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2016</study_first_posted>
  <last_update_submitted>February 1, 2018</last_update_submitted>
  <last_update_submitted_qc>February 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nicklaus Children's Hospital f/k/a Miami Children's Hospital</investigator_affiliation>
    <investigator_full_name>Christopher Tirotta</investigator_full_name>
    <investigator_title>Director Cardiac Anesthesia</investigator_title>
  </responsible_party>
  <keyword>CBP, congenital heart defects, cardiopulmonary bypass</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Afibrinogenemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

